Full Text Journal Articles by
Author Stephen H Culp

Advertisement

Find full text journal articles






Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options.

Nicholas G Zaorsky, Daniel E Spratt, Amar U Kishan, Stephen H Culp, Timothy N Showalter,

Front Oncol (Frontiers in oncology)
[2020, 10:1616]

Cited: 0 times

View full text PDF listing >>



Prostate Cancer Characteristics in the US Preventive Services Task Force Grade D Era: A Single-Center Study and Meta-Analysis.

Matthew B Clements, Basil Abdalla, Stephen H Culp, Raymond A Costabile, Tracey L Krupski,

<h4>Background</h4>In May 2012, the US Preventive Services Task Force assigned prostate-specific antigen-based screening a grade D recommendation, advising against screening at any age. Our objective was to compare prostate cancer characteristics pre- and post-recommendation with an adjusted analysis of our data and a pooled analysis including other primary data sources.<h4>Methods</h4>We ... Read more >>

Urol Int (Urologia internationalis)
[2020, 104(9-10):692-698]

Cited: 1 time

View full text PDF listing >>



Advertisement

Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.

Andrew G McIntosh, Eric C Umbreit, Levi C Holland, Cindy Gu, Nizar M Tannir, Surena F Matin, Jose A Karam, Stephen H Culp, Christopher G Wood,

<h4>Background</h4>The management of metastatic renal cell carcinoma (mRCC) has evolved rapidly, and results from the Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial bring into question the utility of cytoreductive nephrectomy (CN). The objective of this study was to examine overall survival (OS) and identify risk factors associated with ... Read more >>

Cancer (Cancer)
[2020, 126(17):3950-3960]

Cited: 2 times

View full text PDF listing >>



Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.

Jennifer Y Ju, Anne M Mills, Mani S Mahadevan, Jinbo Fan, Stephen H Culp, Martha H Thomas, Helen P Cathro,

Lynch syndrome (LS) is defined by germline mutations in DNA mismatch repair (MMR) genes, and affected patients are at high risk for multiple cancers. Reflexive testing for MMR protein loss by immunohistochemistry (IHC) is currently only recommended for colorectal and endometrial cancers, although upper tract urothelial carcinoma (UTUC) is the ... Read more >>

Am J Surg Pathol (The American journal of surgical pathology)
[2018, 42(11):1549-1555]

Cited: 7 times

View full text PDF listing >>



Robotic-Assisted Surgery for Upper Tract Urothelial Carcinoma: A Comparative Survival Analysis.

Matthew B Clements, Tracey L Krupski, Stephen H Culp,

<h4>Background</h4>We performed a comparative survival analysis of patients undergoing robotic-assisted versus laparoscopic or open surgery for upper tract urothelial carcinoma (UTUC).<h4>Materials and methods</h4>Patients diagnosed with non-metastatic UTUC undergoing removal of the kidney and/or ureter were identified using Medicare-linked Surveillance, Epidemiology, and End Results Program data (2004-2013). Patients aged 65-85 years were ... Read more >>

Ann Surg Oncol (Annals of surgical oncology)
[2018, 25(9):2550-2562]

Cited: 0 times

View full text PDF listing >>



Prostatic Artery Chemoembolization-A Viable Management Option for Men Diagnosed with Prostate Cancer?

Stephen H Culp,

J Vasc Interv Radiol (Journal of vascular and interventional radiology : JVIR)
[2018, 29(3):306]

Cited: 1 time

View full text PDF listing >>



Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.

Stephen H Culp,

The beneficial effect of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma in the immunotherapy era was based on two prospective randomized trials. Unfortunately, such evidence does not yet exist in the present-day period of targeted therapy. Despite this, cytoreductive nephrectomy remains integral in the multimodal management ... Read more >>

Ther Adv Urol (Therapeutic advances in urology)
[2015, 7(5):275-285]

Cited: 7 times

View full text PDF listing >>



Penile cancer: new insights into the "way forward" for this rare disease.

Stephen H Culp, Curtis A Pettaway,

J Urol (The Journal of urology)
[2015, 193(2):394-395]

Cited: 0 times

View full text PDF listing >>



Reconciling the use of cytoreductive nephrectomy in the targeted therapy era.

Stephen H Culp,

Eur Urol (European urology)
[2014, 66(4):711-712]

Cited: 1 time

View full text PDF listing >>



Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.

Stephen H Culp, Jose A Karam, Christopher G Wood,

OBJECTIVES: Despite level 1 evidence demonstrating a survival benefit of cytoreductive nephrectomy (CN) in well-selected patients with metastatic renal cell carcinoma (mRCC) in the cytokine era, its role in the contemporary period of targeted therapy remains understudied. To help facilitate improved patient selection for CN and clinical trial design in ... Read more >>

Urol Oncol (Urologic oncology)
[2014, 32(5):561-568]

Cited: 12 times

View full text PDF listing >>



Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Stephen H Culp, Paul F Schellhammer, Michael B Williams,

<h4>Background</h4>Few data exist regarding the impact on survival of definitive treatment of the prostate in men diagnosed with metastatic prostate cancer (mPCa).<h4>Objective</h4>To evaluate the survival of men diagnosed with mPCa based on definitive treatment of the prostate.<h4>Design, setting, and participants</h4>Men with documented stage IV (M1a-c) PCa at diagnosis identified using ... Read more >>

Eur Urol (European urology)
[2014, 65(6):1058-1066]

Cited: 166 times

View full text PDF listing >>



Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.

Stephen H Culp, Rian J Dickstein, H Barton Grossman, Shanna M Pretzsch, Sima Porten, Siamak Daneshmand, Jie Cai, Susan Groshen, Arlene Siefker-Radtke, Randall E Millikan, Bogdan Czerniak, Neema Navai, Matthew F Wszolek, Ashish M Kamat, Colin P N Dinney,

<h4>Purpose</h4>We evaluated the survival of patients with muscle invasive bladder cancer undergoing radical cystectomy without neoadjuvant chemotherapy to confirm the utility of existing clinical tools to identify low risk patients who could be treated with radical cystectomy alone and a high risk group most likely to benefit from neoadjuvant chemotherapy.<h4>Materials ... Read more >>

J Urol (The Journal of urology)
[2014, 191(1):40-47]

Cited: 80 times

View full text PDF listing >>



Lower urinary tract symptom improvement after radical prostatectomy correlates with degree of prostatic inflammation.

Michael B Burris, Helen P Cathro, Casey G Kowalik, Drew Jensen, Stephen H Culp, William D Steers, Tracey L Krupski,

<h4>Objective</h4>To determine if prostatic inflammation at the time of radical prostatectomy (RP) was associated with the International Prostate Symptom Score (IPSS).<h4>Methods</h4>We performed a proof of principle analytic case control study of patients who underwent RP between January 2005 and August 2008 for lower urinary tract symptoms (LUTS). We reviewed pathology ... Read more >>

Urology (Urology)
[2014, 83(1):186-190]

Cited: 3 times

View full text PDF listing >>



Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Vitaly Margulis, Shahrokh F Shariat, Yury Rapoport, Michael Rink, Daniel D Sjoberg, Nizar M Tannir, E Jason Abel, Stephen H Culp, Pheroze Tamboli, Christopher G Wood,

<h4>Background</h4>There is limited evidence to guide patient selection for cytoreductive nephrectomy (CN) following the diagnosis of metastatic renal cell carcinoma (mRCC).<h4>Objective</h4>Given the significant variability in oncologic outcomes following surgery, we sought to develop clinically relevant, individualized, multivariable models for the prediction of cancer-specific survival at 6 and 12 mo after ... Read more >>

Eur Urol (European urology)
[2013, 63(5):947-952]

Cited: 40 times

View full text PDF listing >>



Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.

E Jason Abel, Alonso Carrasco, Stephen H Culp, Surena F Matin, Pheroze Tamboli, Nizar M Tannir, Christopher G Wood,

<h4>Unlabelled</h4>Study Type--Diagnostic (cohort) Level of Evidence: 2b. What's known on the subject? and What does the study add? Although there have been many investigations of biopsy for small renal masses, there are scant data on the accuracy of biopsy in the setting of metastatic renal cell carcinoma (mRCC). We report ... Read more >>

BJU Int (BJU international)
[2012, 110(11):1742-1746]

Cited: 23 times

View full text PDF listing >>



Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.

Brian F Chapin, Scott E Delacroix, Stephen H Culp, Graciela M Nogueras Gonzalez, Nizar M Tannir, Eric Jonasch, Pheroz Tamboli, Christopher G Wood,

<h4>Background</h4>In patients with metastatic renal cell carcinoma (mRCC), the timing of systemic targeted therapy in relation to cytoreductive nephrectomy (CN) is under investigation.<h4>Objective</h4>To evaluate postoperative complications after the use of presurgical targeted therapy prior to CN.<h4>Design, setting, and participants</h4>A retrospective review of all patients who underwent a CN at The ... Read more >>

Eur Urol (European urology)
[2011, 60(5):964-971]

Cited: 47 times

View full text PDF listing >>



Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.

E Jason Abel, Stephen H Culp, Nizar M Tannir, Pheroze Tamboli, Surena F Matin, Christopher G Wood,

<h4>Background</h4>In metastatic renal cell carcinoma (mRCC) patients treated with targeted agents and their primary tumor (PT) in situ, early PT decrease in size correlates with improved overall PT response, but the effect on overall survival (OS) is unknown.<h4>Objective</h4>To evaluate whether early PT size reduction is associated with improved OS in ... Read more >>

Eur Urol (European urology)
[2011, 60(6):1273-1279]

Cited: 43 times

View full text PDF listing >>



Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment.

E Jason Abel, Stephen H Culp, Surena F Matin, Pheroze Tamboli, Michael J Wallace, Eric Jonasch, Nizar M Tannir, Christopher G Wood,

<h4>Purpose</h4>As treatment options evolve for metastatic renal cell carcinoma, there is a need for predictive information to help guide therapy. We assessed the accuracy of percutaneous primary tumor biopsy for metastatic renal cell carcinoma by comparing biopsy findings to final nephrectomy pathology in patients undergoing cytoreductive nephrectomy.<h4>Materials and methods</h4>Using an ... Read more >>

J Urol (The Journal of urology)
[2010, 184(5):1877-1881]

Cited: 37 times

View full text PDF listing >>



Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.

Jose A Karam, Xiu-Ying Zhang, Pheroze Tamboli, Vitaly Margulis, Hua Wang, E Jason Abel, Stephen H Culp, Christopher G Wood,

<h4>Background</h4>Animal models are instrumental in understanding disease pathophysiology and mechanisms of therapy action and resistance in vivo.<h4>Objective</h4>To establish and characterize a panel of mouse models of renal cell carcinoma (RCC) derived from patients undergoing radical nephrectomy.<h4>Design, setting, and participants</h4>In vivo and in vitro animal experiments.<h4>Measurements</h4>Tumor tissues obtained during surgery were ... Read more >>

Eur Urol (European urology)
[2011, 59(4):619-628]

Cited: 40 times

View full text PDF listing >>



Identifying the risk of disease progression after surgery for localized renal cell carcinoma.

E Jason Abel, Stephen H Culp, Matthew Meissner, Surena F Matin, Pheroze Tamboli, Christopher G Wood,

<h4>Objective</h4>To identify factors in a large cohort of patients with pathologically localized renal cell carcinoma (RCC) that predicted disease progression after surgery, as RCC most commonly presents as a localized tumour which is treated with surgical excision.<h4>Patients and methods</h4>Using an institutional database, we identified all patients who underwent radical or ... Read more >>

BJU Int (BJU international)
[2010, 106(9):1277-1283]

Cited: 12 times

View full text PDF listing >>



Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.

E Jason Abel, Stephen H Culp, Nizar M Tannir, Surena F Matin, Pheroze Tamboli, Eric Jonasch, Christopher G Wood,

<h4>Background</h4>The recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and optimal timing of cytoreductive nephrectomy is being reevaluated.<h4>Objective</h4>To determine primary tumor response to treatment with targeted agents in patients with mRCC.<h4>Design, setting, and participants</h4>We reviewed the clinical and ... Read more >>

Eur Urol (European urology)
[2011, 59(1):10-15]

Cited: 67 times

View full text PDF listing >>



Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Stephen H Culp, Nizar M Tannir, E Jason Abel, Vitaly Margulis, Pheroze Tamboli, Surena F Matin, Christopher G Wood,

<h4>Background</h4>The benefits of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) should outweigh surgical morbidity. Even when the generally agreed upon selection criteria for CN are met, some patients do poorly after surgery. The objective of this study was to identify preoperative factors that were prognostic of outcome in ... Read more >>

Cancer (Cancer)
[2010, 116(14):3378-3388]

Cited: 89 times

View full text PDF listing >>



Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection?

Stephen H Culp, Christopher G Wood,

While several retrospective studies have suggested a possible benefit of lymph node dissection (LND) for patients with clinically node-positive renal cell carcinoma (RCC), the value of LND in patients with clinically node-negative RCC has remained uncertain. LND undoubtedly improves the accuracy of staging and provides better prognostic information; however, much ... Read more >>

Nat Clin Pract Urol (Nature clinical practice. Urology)
[2009, 6(3):126-127]

Cited: 2 times

View full text PDF listing >>



Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo- controlled phase III trial.

Stephen H Culp, Christopher G Wood,

Eur Urol (European urology)
[2009, 55(6):1484-1485]

Cited: 0 times

View full text PDF listing >>



Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.

Hong Gee Sim, Donatello Telesca, Stephen H Culp, William J Ellis, Paul H Lange, Lawrence D True, Daniel W Lin,

<h4>Purpose</h4>Gleason sum 7 prostate cancers are a heterogeneous group with diverse tumor behaviors and disease outcomes. Tertiary Gleason patterns are reported with increasing frequency, particularly in prostatectomy pathology reports. We studied the pathological and biochemical outcome following radical prostatectomy in men with Gleason sum 7 and tertiary Gleason pattern 5.<h4>Materials ... Read more >>

J Urol (The Journal of urology)
[2008, 179(5):1775-1779]

Cited: 48 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0309 s